MARKET

SBBP

SBBP

Strongbridge
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.770
-0.120
-6.35%
Closed 16:00 04/01 EDT
OPEN
1.810
PREV CLOSE
1.890
HIGH
1.830
LOW
1.710
VOLUME
139.51K
TURNOVER
--
52 WEEK HIGH
5.05
52 WEEK LOW
1.430
MARKET CAP
96.02M
P/E (TTM)
-1.9393
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SBBP stock price target is 6.64 with a high estimate of 9.00 and a low estimate of 5.00.

EPS

SBBP News

More
  • Edited Transcript of SBBP earnings conference call or presentation 25-Feb-20 1:30pm GMT
  • Thomson Reuters StreetEvents · 03/07 05:26
  • Benzinga's Top Upgrades, Downgrades For March 3, 2020
  • Benzinga · 03/03 15:06
  • Craig-Hallum Initiates Coverage On Strongbridge Biopharma with Buy Rating, Announces $7.5 Price Target
  • Benzinga · 03/03 13:10
  • If You Had Bought Strongbridge Biopharma (NASDAQ:SBBP) Shares Five Years Ago You'd Have Made 139%
  • Simply Wall St. · 02/27 13:35

Industry

Pharmaceuticals
-2.46%
Pharmaceuticals & Medical Research
-2.91%

Hot Stocks

Symbol
Price
%Change

About SBBP

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing's syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).
More

Webull offers kinds of Strongbridge Biopharma plc stock information, including NASDAQ:SBBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SBBP stock news, and many more online research tools to help you make informed decisions.